At the nucleus of cancer: how the nuclear envelope controls tumor progression.

Historically considered downstream effects of tumorigenesis-arising from changes in DNA content or chromatin organization-nuclear alterations have long been seen as mere prognostic markers within a genome-centric model of cancer. However, recent findings have placed the nuclear envelope (NE) at the forefront of tumor progression, highlighting its active role in mediating cellular responses to mechanical forces. Despite significant progress, the precise interplay between NE components and cancer progression remains under debate.

Validation of the generalized stochastic microdosimetric model (GSM2) over a broad range of LET and particle beam type: a unique model for accurate description of (therapy relevant) radiation qualities.

. The present work shows the first extensive validation of the(GSM). This mechanistic and probabilistic model is trained and tested over cell survival experiments conducted with two cell lines (H460 and H1437), three different types of radiation (protons, helium, and carbon ions), spanning a very broad LET range from1 keVμm-1up to more than300 keVμm-1.

Estrogen-related differences in antitumor immunity and gut microbiome contribute to sexual dimorphism of colorectal cancer.

Colorectal cancer (CRC) is a multifaceted disease whose development and progression varies depending on tumor location, age of patients, infiltration of immune cells within cancer lesions, and the tumor microenvironment. These pathophysiological characteristics are additionally influenced by sex-related differences. The gut microbiome plays a role in initiation and progression of CRC, and shapes anti-tumor immune responses but how responsiveness of the immune system to the intestinal microbiota may contribute to sexual dimorphism of CRC is largely unknown.